Altimmune’s pemvidutide shows promise in MASH but lags on fibrosis vs. rivals. Learn what upcoming data means for ALT stock ...

Targeting GLP-1 receptors now has the FDA’s blessing as a way to treat the fatty liver disease called MASH with Novo Nordisk’s weekly injectable drug Wegovy becoming the second approved treatment for ...

Wegovy has been approved for use among the growing number of Americans who have MASH.

Participants at Creative 360's End of Summer Mash-Up on Aug. 11 outlined squishy designs after watching the movie "Encanto" for inspiration.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has received conditional marketing approval from the European Commission for its liver-directed drug Rezdiffra (resmetirom), intended for treating non ...

Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. Shortly after market close ...

On Friday, the FDA granted accelerated approval to Novo Nordisk’s Wegovy for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis but without ...

The combination of ervogastat plus clesacostat was more effective at resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in patients with biopsy-confirmed MASH ...

Wegovy is first GLP-1 treatment approved for MASH FDA decision based on part one of an ongoing study Novo Nordisk seeks approval in Europe and Japan Aug 15 (Reuters) - Novo Nordisk (NOVOb.CO), opens ...